Merck Downgraded from Strong Buy Amid High Expectations

Merck & Co., Inc. has seen significant growth since my last bullish call, surging 72% versus the benchmark's 15%. The company now trades at a price-to-earnings ratio of 14x for its forward 15-month earnings, but lofty expectations for FY2027 limit room for error.

The analyst downgraded Merck from Strong Buy to Hold, preferring to wait for fundamentals to catch up. While the stock remains a defensive and yield-generating diversification play, near-term upside appears constrained by valuation and expectations.